MDRX:NSD-Veradigm Inc. (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 9.725

Change

-0.03 (-0.26)%

Market Cap

USD 1.04B

Volume

8.06K

Analyst Target

USD 9.97
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
GEHC GE HealthCare Technologies Inc..

+1.74 (+2.00%)

USD 39.63B
HQY HealthEquity Inc

-1.26 (-1.60%)

USD 6.83B
RCM R1 RCM Inc

+0.02 (+0.14%)

USD 5.96B
GDRX Goodrx Holdings Inc

-0.24 (-3.16%)

USD 2.94B
BTSG BrightSpring Health Services, ..

+0.23 (+1.57%)

USD 2.37B
PRVA Privia Health Group Inc

+0.27 (+1.44%)

USD 2.23B
PINC Premier Inc

-0.05 (-0.24%)

USD 2.03B
OMCL Omnicell Inc

-2.14 (-4.76%)

USD 1.99B
CERT Certara Inc

+0.10 (+0.92%)

USD 1.76B
SDGR Schrodinger Inc

+0.10 (+0.51%)

USD 1.48B

ETFs Containing MDRX

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.29% 64% D 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.29% 63% D 40% F
Trailing 12 Months  
Capital Gain -23.30% 53% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.30% 53% F 30% F
Trailing 5 Years  
Capital Gain -10.78% 65% D 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.78% 65% D 39% F
Average Annual (5 Year Horizon)  
Capital Gain 16.21% 78% C+ 74% C
Dividend Return 16.21% 77% C+ 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 59.45% 27% F 30% F
Risk Adjusted Return 27.26% 78% C+ 61% D-
Market Capitalization 1.04B 78% C+ 72% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.